SAB Biotherapeutics, Inc. (SABSW)
NCM
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
Peers in industry
SAB Biotherapeutics, Inc. has no peer companies in this window.
Recent press releases
April 2026
SAB Biotherapeutics SABSW shows preserved insulin production in early diabetes trial
# 📢 What This Document Is This is an **8-K filing**—a report public companies use to announce major news to investors. Here, SAB Biotherapeutics (ticker: SABS) is sharing **exciting new clinical trial data** that was just presented at a major medical conference. Think of it as a detailed press rele
SEC filings
All filings →Insider trades
All insider trades →SAB Biotherapeutics, Inc. has no reported insider trades in the last 90 days.
Institutional holders
All holders →People at SAB Biotherapeutics, Inc.
All people →No officers or directors have been indexed for SAB Biotherapeutics, Inc..